HENRIETTA, N.Y.--(BUSINESS WIRE)--Kamal Sarbadhikari, CEO, SensiVida Medical Technologies, Inc. (OTCBB:SVMT), announced that on June 16, 2009, the company received written clearance from the Western Institutional Review Board (WIRB) of Olympia, Washington, to begin clinical trials of its minimally invasive allergy test system. The WIRB stated, “The Board determined that the device as used in the research study is a non-significant risk device.” CEO Sarbadhikari said, “given this important ‘green light,’ we are now poised to begin human clinical trials” and are pleased that the WIRB agrees with the company’s position that our microsystems-based digital allergy test device is a non-significant risk device.
